Bone Biologics (BBLG) Other Accumulated Expenses (2013)
Bone Biologics (BBLG) posted quarterly Other Accumulated Expenses of $75000.0 for Q4 2013.
Powered by 
Analysis
Bone Biologics (BBLG) Other Accumulated Expenses (2013) Analysis & Trends
Bone Biologics (BBLG) has reported Other Accumulated Expenses for 1 consecutive years, with $75000.0 the latest figure, recorded in Q4 2013.
- In Q4 2013, Other Accumulated Expenses changed N/A year-over-year to $75000.0; the TTM figure through Dec 2013 stood at $75000.0 (changed N/A YoY), while the FY2013 annual figure was $75000.0, changed N/A from the prior year.
- Other Accumulated Expenses was little changed at $75000.0 in Q4 2013 per BBLG's latest filing.
- Across five years, Other Accumulated Expenses topped out at $75000.0 in Q4 2013 and bottomed at $75000.0 in Q4 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - |